Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hengmiao Cheng

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure-activity relationship studies of 5-alkylethers and 5-thioethersSubas M Sakya, Hengmiao Cheng, Kristin M Lundy Demello, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2010
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitorsKevin K-C Liu, Shubha Bagrodia, Simon Bailey, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2005
5-heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure-activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analogSubas M Sakya, Kristin M Lundy DeMello, Martha L Minich, et al.
Bioorganic & Medicinal Chemistry Letters|March 16, 2013
N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: strategies to eliminate reactive metabolitesSajiv K Nair, Jean J Matthews, Stephan J Cripps, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2006
Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitorsHengmiao Cheng, Kristin M Lundy DeMello, Jin Li, et al.
Journal of Medicinal Chemistry|December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Journal of Medicinal Chemistry|March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure-activity relationship studies of 5-alkylethers and 5-thioethersSubas M Sakya, Hengmiao Cheng, Kristin M Lundy Demello, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2010
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitorsKevin K-C Liu, Shubha Bagrodia, Simon Bailey, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2005
5-heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure-activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analogSubas M Sakya, Kristin M Lundy DeMello, Martha L Minich, et al.
Bioorganic & Medicinal Chemistry Letters|March 16, 2013
N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: strategies to eliminate reactive metabolitesSajiv K Nair, Jean J Matthews, Stephan J Cripps, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2006
Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitorsHengmiao Cheng, Kristin M Lundy DeMello, Jin Li, et al.
Journal of Medicinal Chemistry|December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Journal of Medicinal Chemistry|March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 3